Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson's disease

Zorginstituut Nederland has approved a pharmacotherapeutic report for the medicine safinamide (Xadago®). They reached the following conclusion.Based on the criteria of the Medicines Reimbursement System (GVS), safinamide can be includedin the GVS on List 1A in cluster 0N04BD AO V, with a standard dose of 75mg.